These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 18486227

  • 1. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K.
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [Abstract] [Full Text] [Related]

  • 2. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ, Johnson DM, Weltens E, Lissens J.
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [Abstract] [Full Text] [Related]

  • 3. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Sep; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 4. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK, Hancox JC, Curtis MJ.
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L, Breschi MC, Martinotti E, Calderone V.
    J Appl Toxicol; 2007 Aug; 27(3):270-5. PubMed ID: 17265420
    [Abstract] [Full Text] [Related]

  • 7. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N, Authier S, Pugsley MK, Curtis MJ.
    Toxicol Appl Pharmacol; 2010 Mar 01; 243(2):146-53. PubMed ID: 20005885
    [Abstract] [Full Text] [Related]

  • 8. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
    Takahara A, Sugiyama A, Hashimoto K.
    Br J Pharmacol; 2005 Oct 01; 146(4):561-7. PubMed ID: 16056235
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo models for testing arrhythmogenesis in drugs.
    Carlsson L.
    J Intern Med; 2006 Jan 01; 259(1):70-80. PubMed ID: 16336515
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
    Mok NS, Lo YK, Tsui PT, Lam CW.
    J Cardiovasc Electrophysiol; 2005 Dec 01; 16(12):1375-7. PubMed ID: 16403073
    [Abstract] [Full Text] [Related]

  • 12. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M, Kimura K, Ito S.
    J Pharmacol Toxicol Methods; 2007 Dec 01; 55(3):254-61. PubMed ID: 17229580
    [Abstract] [Full Text] [Related]

  • 13. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes.
    Carlsson L.
    Pharmacol Ther; 2008 Aug 01; 119(2):160-7. PubMed ID: 18558435
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
    Webster R, Leishman D, Walker D.
    Curr Opin Drug Discov Devel; 2002 Jan 01; 5(1):116-26. PubMed ID: 11865665
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
    Gallacher DJ, Van de Water A, van der Linde H, Hermans AN, Lu HR, Towart R, Volders PG.
    Cardiovasc Res; 2007 Nov 01; 76(2):247-56. PubMed ID: 17669388
    [Abstract] [Full Text] [Related]

  • 19. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL, Kung MF.
    Pharmacoepidemiol Drug Saf; 2009 Mar 01; 18(3):235-9. PubMed ID: 19145580
    [Abstract] [Full Text] [Related]

  • 20. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V, Cavero I.
    Minerva Med; 2002 Jun 01; 93(3):181-97. PubMed ID: 12094149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.